000 | 01003 a2200253 4500 | ||
---|---|---|---|
005 | 20250515134013.0 | ||
264 | 0 | _c20090106 | |
008 | 200901s 0 0 eng d | ||
022 | _a0738-081X | ||
024 | 7 |
_a10.1016/j.clindermatol.2007.10.027 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSchön, Michael P | |
245 | 0 | 0 |
_aEfalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety. _h[electronic resource] |
260 |
_bClinics in dermatology _c |
||
300 |
_a509-14 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
650 | 0 | 4 |
_aCD11a Antigen _ximmunology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
773 | 0 |
_tClinics in dermatology _gvol. 26 _gno. 5 _gp. 509-14 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clindermatol.2007.10.027 _zAvailable from publisher's website |
999 |
_c18226025 _d18226025 |